Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | High-Frequency Electrical Stimulation Pulses With or Without a Low Dose Local Anesthetic for the Treatment of Pain | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Functional Neuromuscular Electrical Stimulation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Electromyography and Nerve Conduction Studies (Electrodiagnostic Assessment) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Electrical Stimulation and Electromagnetic Therapy for the Treatment of Wounds | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Electrical and Electromagnetic Stimulation for the Treatment of Arthritis | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Electrical Impedance Scanning of the Breast | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Idursulfase (Elaprase) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Elapegademase-lvir(Revcovi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Mirvetuximab Soravtansine-gynx (Elahere) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Eladocagene exuparvovec-tneq (Kebilidi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Eflapegrastim-xnst (Rolvedon) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Efgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (VyvgartHytrulo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Efbemalenograstim alfa-vuxw (Ryzneuta) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Edaravone (Radicava) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Eculizumab Products (Soliris, Bkemv [Eculizumab-aeeb], and Epysqli [Eculizumab-aagh]) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ecallantide (Kalbitor) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Dynamic Posturography in the Assessment of Balance | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Durvalumab (Imfinzi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hyaluronic Acid Derivatives: Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Hymovis One, Monovisc, Orthovisc, Supartz FX, Synojoynt, Synvisc, & Synvisc-One, Triluron, TriVisc, VISCO-3 | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Dostarlimab-gxly (Jemperli) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Donor Lymphocyte Infusion for Hematologic Malignancies Treated with an Allogeneic Hematopoietic Stem Cell Transplant | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Donanemab-azbt (Kisunla) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Digital Health Therapies for Substance Use Disorders | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Digital Health Therapies for Attention Deficit/Hyperactivity Disorder (ADHD) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Digital Health Technologies: Diagnostic Applications | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nonoperative Diagnostic Spinal Ultrasound (Echography/Sonogram) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Facet Joint Injections | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Diabetes Management | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Dexamethasone Implant (Ozurdex) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Whole Body Dual X-Ray Absorptiometry (DEXA) to Determine Body Composition | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Denosumab Products: (Xgeva); Denosumab-kyqq (Aukelso); Denosumab-nxxp (Bilprevda); Denosumab-bnht (Bomyntra); Denosumab-desu (Jubereq); Denosumab-bmwo (Osenvelt); Denosumab-mobz (Oziltus); Denosumab-bbdz (Wyost); Denosumab-dssb (Xbryk), Denosumab-qbde (Xtrenbo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Denosumab Products: (Prolia); Denosumab-nxxp (Bildyos); Denosumab-mobz (Boncresa);Denosumab-kyqq (Bosaya); Denosumab-bnht (Conexxence); Denosumab-qbde (Enoby); Denosumab-bbdz (Jubbonti); Denosumab-dssb (Ospomyv); Denosumab-desu (Osvyrti); Denosumab-bmwo (Stoboclo | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Denileukin diftitox-cxdl (Lymphir) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Delandistrogene moxeparvovec-rokl (Elevidys) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Degarelix (Firmagon) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | DaxibotulinumtoxinA-lanm (Daxxify) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Datopotamab Deruxtecan-dlnk (Datroway) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Daratumumab and hyaluronidase-fihj (Darzalex Faspro) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Daratumumab (Darzalex) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Naxitamab-gqgk (Danyelza) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Daily Hemodialysis in the Home | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Daunorubicin and Cytarabine, Liposome (Vyxeos) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ramucirumab (Cyramza) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | SCIG (Immune Globulin SQ): Hizentra, Hyqvia, Cuvitru, Cutaquig, Xembify | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Cutaneous Electrogastrography (EGG) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Quantitative Sensory Testing | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Cryosurgical Ablation of Solid Tumors | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Crovalimab-akkz (Piasky) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Cranial Electrotherapy Stimulation | Criteria changed |